Abstract
Diabetes is a leading cause of ESKD worldwide, resulting in substantial patient morbidity and healthcare costs. Fenofibrate and other fibrate therapies may improve lipid profiles and prevent cardiovascular events in people with CKD, and thus may be useful as adjunctive therapies to reduce the risk
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical journal of the American Society of Nephrology : CJASN
Paper Title
Journal
Date
